Picture of Bioventix logo

BVXP Bioventix News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareBalancedSmall CapHigh Flyer

REG-Bioventix Plc: Collaboration with Pre Diagnostics AS <Origin Href="QuoteRef">BVXP.L</Origin>

    
 
 Press release 
 
 Bioventix plc 
 
 (“Bioventix” or the “Company”) 
 
 Pre Diagnostics and Bioventix enter collaboration on blood-based beta amyloid
Alzheimer’s diagnostic test 
 
 Oslo, 31 May 2016, Norwegian Alzheimer’s diagnostics company Pre
Diagnostics AS today announced a collaboration with leading UK antibody
specialist Bioventix plc (BVXP).  Under the terms of the agreement Bioventix
will develop and provide antibodies for Pre Diagnostics new patient-friendly
IVD test for dementia based on mid domain beta amyloid detection. 
 
 The inventor of Pre Diagnostics’ approach, Professor Tormod Fladby of
Akershus University Hospital and the University of Oslo commented on the
clinical need: “Alzheimer's disease develops over many years and the brain
adapts to the disease.  It can take 10-20 years before dementia onset.  By
then is it too late to reverse the disease symptoms and brain degeneration.
 Early detection of disease activity is likely to allow more effective
treatment early in the disease course, and may improve quality of life and
delay disease progression for patients with Alzheimer's disease.  Our
research, on which the new test is based, shows that Alzheimer’s disease is
accompanied by systemic responses in certain white blood cells (macrophages)
unique to the disease which can be accurately measured in the blood samples of
patients.” 
 
 Pre Diagnostics CEO Håkon Sæterøy commented.  “By working with
Bioventix, utilising their in-depth antibody and ELISA expertise, we aim to
further optimise our current prototype blood-based Alzheimer’s test which
has already shown promise in preliminary testing”.  
 
 According to Sæterøy, the company is now on track for launching a research
only test in 2017:  “It is now widely accepted that a new blood-based test
with high accuracy in the early disease stages is essential to accelerate
effective drug development and intervention within the Alzheimer’s space.
 We aim to develop such tests that effectively demonstrate any intervention
effect on the key disease mechanisms.” 
 
 Peter Harrison, CEO of Bioventix plc said: “We are delighted to be involved
with Pre Diagnostics and their beta amyloid project.  We are very impressed
by the Oslo-based group and their research partners, their thorough approach
to basic science and their ability to apply this to clinical research.  We
believe that our antibody and assay capabilities can be applied to beta
amyloid, thus facilitating an improved Alzheimer test for the Oslo group.  It
will be exciting to work with them towards further clinical testing and
commercialisation”.   
 
 For further information, please contact: 
 
  Pre Diagnostics AS Håkon Sæterøy Bioventix plc Peter Harrison    Chief Executive Officer Chief Executive Officer    Tel: +47 956 95 175  Tel: 01252 728 001   
                                                                                                                                                                     
  finnCap Ltd Geoff Nash/Simon Hicks Steve Norcross                   Corporate Finance Corporate Broking                Tel: 020 7220 0500                          
 
 About Pre Diagnostics AS 
 
 Pre Diagnostics (www.pre-diagnostics.com) is an innovative Norwegian
diagnostic company that seeks to create value for patients, partners, and
investors by developing pioneering and patient-friendly, in-vitro diagnostic
(IVD) products for early detection of diseases. The company’s proprietary
concept is built upon the scientific premise that a disease evokes systemic
responses in macrophages unique to that disease which can be accurately
measured in the blood samples of patients. Pre Diagnostics aims to be a leader
in the diagnosis of early Alzheimer’s disease and is thus focused on the
development of IVD biomarker products that use well-established technologies
and procedures. The company protects its technology with an evolving patent
portfolio             
 
 About Bioventix plc: 
 
 Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing.  The antibodies created at Bioventix are generated in sheep
and are of particular benefit where the target is present at low concentration
and where conventional monoclonal or polyclonal antibodies have failed to
produce a suitable reagent.  Bioventix currently offers a portfolio of
antibodies to customers for both commercial use and R&D purposes, for the
diagnosis or monitoring of a broad range of conditions, including heart
disease, cancer, fertility, thyroid function and drug abuse.  Bioventix
currently supplies antibody products and services to the majority of
multinational clinical diagnostics companies.  Bioventix is based in Farnham,
UK and its shares are traded on AIM under the symbol BVXP. 
 
 About Alzheimer’s disease: 
 
 Alzheimer disease is the leading cause of dementia among older people. An
estimated 10 percent of Americans over the age of 65 and half of those over
age 85 have Alzheimer's. More than five million Americans currently suffer
from the disease, and the number is projected to balloon to 10-15 million over
the next several decades. Alzheimer's is now the third most expensive disease
to treat in the U.S., costing society close to $100 billion annually. 
 
 Alzheimer's is a progressive, incurable disease. The earliest damage occurs
in the entorhinal cortex, hippocampus and basal forebrain, which are small,
specialized structures in the brain that play a critical role in memory. The
disease is characterized by amyloid plaques (deposits in the brain of a sticky
protein called amyloid beta peptide) and neurofibrillary tangles (abnormally
twisted forms of the protein tau, in the long branches of neurons). The cause
remains a mystery. 
 


Copyright (c) 2016 PR Newswire Association,LLC. All Rights Reserved

Recent news on Bioventix

See all news